Myungmoon Pharm명문제약
017180 · KOSPI · ₩017180 · 명문제약
Valuation model · Discounted cash flow (DCF)
We use a 5-year discounted cash flow: the value of the cash the business is expected to produce, in today's money.
Fair value per share
₩1,097
vs the current price (₩1,136)
- Enterprise value
- ₩52B
- Equity value
- ₩37B
- WACC
- 6.5%
Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal. This is not financial advice.
Bear / Base / Bull
- Bear
- —
- Base
- ₩1,097
- −3.4%
- Bull
- ₩4,975
- +337.9%
Bear: revenue growth 3 points lower every year, EBIT margin 2 points lower, WACC 1 point higher. Bull: the opposite.
Assumptions
Sign in to change the assumptions and see the results update. Sign in
Cycle options
Margin path
Every year uses the cycle-average margin (1.5%).
Revenue growth
- 8.7%
How much sales grow that year, compared with the year before.
Default: the last 3 years' revenue growth (8.7% a year, annual reports), fading to 3% by year 5.
- 7.3%
How much sales grow that year, compared with the year before.
Default: the last 3 years' revenue growth (8.7% a year, annual reports), fading to 3% by year 5.
- 5.8%
How much sales grow that year, compared with the year before.
Default: the last 3 years' revenue growth (8.7% a year, annual reports), fading to 3% by year 5.
- 4.4%
How much sales grow that year, compared with the year before.
Default: the last 3 years' revenue growth (8.7% a year, annual reports), fading to 3% by year 5.
- 3%
How much sales grow that year, compared with the year before.
Default: the last 3 years' revenue growth (8.7% a year, annual reports), fading to 3% by year 5.
Business
- 1.5%
Operating profit as a share of revenue.
Default: through-the-cycle average of the last 12 months and the last 5 annual reports' operating margins.
- 27.5%
Share of operating profit paid as corporate tax.
Default: Korea's top corporate tax rate (25%) plus 10% local income tax.
- 2%
The non-cash cost of wearing out equipment, added back to cash flow (% of revenue).
Default: average of the last 3 annual reports (cash flow statements; equipment and intangibles).
- 0.2%
Money spent on factories, equipment, software and other long-term assets (% of revenue).
Default: average of the last 3 annual reports (cash flow statements; equipment and intangibles).
- 11%
Stock and unpaid customer bills, less unpaid supplier bills, as a % of revenue. Each year's extra revenue ties up this much more cash.
Default: working capital (current assets less cash and deposits, minus current liabilities other than borrowings) as a share of revenue, averaged over the last 3 years.
Discount rate
- 2%
How fast cash flows keep growing every year after year 5.
Default: about Korea's long-run inflation plus real growth.
- 4.01%
Yield on Korea's 10-year government bond: the return with almost no risk.
Default: Korea Treasury Bond 10-year yield on 2026-10-30.
- 0.6
How much the share moves when the market moves: 1 means just like the market.
Default: 105 weeks of weekly returns against KOSPI (official index); raw beta 0.02, adjusted toward 1 and kept between 0.6 and 2.0.
- 5.5%
The extra return investors want for owning shares instead of bonds.
Default: a typical premium for Korean shares.
- 5.51%
The interest rate the company would pay to borrow.
Default: the 10-year yield plus a 1.5% credit spread.
Starting point
- Revenue (TTM to H1 2026)
- ₩200B
- Net debt (borrowings and leases − cash and deposits)
- ₩13B
- + Stakes and investments
- ₩2.8B
- Associates, long-term financial assets and deposits (book value)
- − Minority interests
- ₩5.1B
- Shares
- 33,953,454
- Share price
- ₩1,136
- Market cap
- ₩39B
TTM = trailing 12 months: the last four reported quarters added together. "TTM to H1 2026" is the 12 months up to the latest quarterly or half-year report (H1 = to the end of June). Year 1 grows from there.
Past years and projection
Grey columns are reported results from the annual reports (after-tax EBIT at the model's tax rate), so you can check the growth and margin assumptions against the past. Years 1–5 are the model.
| FY2023 | FY2024 | FY2025 | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₩170B | ₩186B | ₩195B | ₩217B | ₩233B | ₩247B | ₩257B | ₩265B |
| Growth | 11.5% | 10.0% | 4.7% | 8.7% | 7.3% | 5.8% | 4.4% | 3.0% |
| EBIT | ₩964M | ₩1.9B | ₩6.8B | ₩3.3B | ₩3.5B | ₩3.7B | ₩3.9B | ₩4B |
| EBIT margin | 0.6% | 1.0% | 3.5% | 1.5% | 1.5% | 1.5% | 1.5% | 1.5% |
| After-tax EBIT | ₩699M | ₩1.4B | ₩5B | ₩2.4B | ₩2.5B | ₩2.7B | ₩2.8B | ₩2.9B |
| + Depreciation | — | — | ₩3.8B | ₩4.3B | ₩4.7B | ₩4.9B | ₩5.1B | ₩5.3B |
| − Capital spending | ₩7.6M | ₩631M | — | ₩434M | ₩466M | ₩493M | ₩515M | ₩530M |
| − Working capital | ₩5.2B | ₩4.8B | −₩41B | ₩1.9B | ₩1.7B | ₩1.5B | ₩1.2B | ₩850M |
| Free cash flow | — | — | — | ₩4.4B | ₩5B | ₩5.6B | ₩6.2B | ₩6.8B |
| Discount factor | — | — | — | 0.939 | 0.882 | 0.828 | 0.778 | 0.731 |
| Present value | — | — | — | ₩4.1B | ₩4.4B | ₩4.7B | ₩4.9B | ₩5B |
Terminal value ₩40B, worth ₩29B today: 56% of enterprise value. It assumes spending settles at 110% of depreciation once growth slows to the terminal rate.
Cross-check: what the market has paid before
For cyclical businesses, analysts check a DCF against the multiples the stock has traded at through past cycles. Price / book is the usual anchor for them: P/E looks highest at the bottom of a cycle, when earnings are smallest, and lowest at the top. The price each band would give today:
| Low | Typical | High | |
|---|---|---|---|
| Price / book (book value ₩2,874 a share)Now 0.40× | ₩1,5600.54× | ₩2,4440.85× | ₩4,2801.49× |
Low, typical and high are the 10th percentile, middle and 90th percentile of month-end multiples since 2021, each against the latest report out by then, per share at today's share count; loss years and P/E above 100 are left out. Run-rate earnings are one quarter × 4, not a forecast. Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal.
Sensitivity
Fair value per share as two inputs change; the middle is the current case.
| WACC ↓ · Terminal growth → | 1.0% | 1.5% | 2.0% | 2.5% | 3.0% |
|---|---|---|---|---|---|
| 5.5% | ₩1,299 | ₩1,353 | ₩1,421 | ₩1,511 | ₩1,637 |
| 6.0% | ₩1,161 | ₩1,196 | ₩1,240 | ₩1,294 | ₩1,367 |
| 6.5% | ₩1,047 | ₩1,070 | ₩1,097 | ₩1,130 | ₩1,172 |
| 7.0% | ₩952 | ₩966 | ₩982 | ₩1,001 | ₩1,024 |
| 7.5% | ₩870 | ₩878 | ₩887 | ₩897 | ₩908 |
Now (TTM)
- Market cap
- ₩39B
- Enterprise value
- ₩51B
- P/E
- —
- P/B
- 0.4×
- P/S
- 0.2×
- EV/EBITDA
- 9.4×
- Dividend yield
- 0.0%
Over time (at each year end)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Price | ₩1,850 | ₩1,819 | ₩2,285 | ₩2,870 | ₩4,730 |
| Market cap | ₩63B | ₩62B | ₩78B | ₩97B | ₩161B |
| P/E | 33.1× | — | — | 12.2× | — |
| P/B | 0.6× | 0.6× | 0.9× | 1.1× | 2.0× |
| P/S | 0.3× | 0.3× | 0.5× | 0.6× | 1.2× |
| EV/EBITDA | 9.7× | — | — | 15.9× | — |
| Dividend yield | 0.0% | — | — | — | — |
Versus similar companies
| Company | P/E | P/B | P/S | EV/EBITDA | Dividend yield |
|---|---|---|---|---|---|
| Myungmoon Pharm | — | 0.4× | 0.2× | 9.4× | 0.0% |
| Samsung Biologics | 34.7× | 8.2× | 15.1× | — | 0.0% |
| Celltrion | 28.2× | 2.5× | 9.1× | — | 0.0% |
| Alteogen | 76.3× | 27.5× | 58.0× | — | 0.1% |
| SK biopharmaceuticals | 15.2× | 6.0× | 7.1× | — | 0.0% |
| Yuhan | 23.3× | 2.3× | 2.4× | 30.4× | 0.8% |
| HLB | — | 15.5× | 54.7× | — | 0.0% |
| Similar companies (median) | 28.2× | 7.1× | 12.1× | 30.4× | 0.0% |
Calculated from end-of-day prices and filed financial statements. Not a recommendation. This is not financial advice.
Also known as: Myungmoon Pharm / 명문제약 / 017180 / KRX:017180
Source: KRX statistical information